141 related articles for article (PubMed ID: 34994597)
41. Prognostic value of tumor mutational burden in patients with oral cavity squamous cell carcinoma treated with upfront surgery.
Moreira A; Poulet A; Masliah-Planchon J; Lecerf C; Vacher S; Larbi Chérif L; Dupain C; Marret G; Girard E; Syx L; Hoffmann C; Jeannot E; Klijanienko J; Guillou I; Mariani O; Dubray-Vautrin A; Badois N; Lesnik M; Choussy O; Calugaru V; Borcoman E; Baulande S; Legoix P; Albaud B; Servant N; Bieche I; Le Tourneau C; Kamal M
ESMO Open; 2021 Aug; 6(4):100178. PubMed ID: 34118772
[TBL] [Abstract][Full Text] [Related]
42. RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.
Rampias T; Giagini A; Siolos S; Matsuzaki H; Sasaki C; Scorilas A; Psyrri A
Clin Cancer Res; 2014 Jun; 20(11):2933-46. PubMed ID: 24696319
[TBL] [Abstract][Full Text] [Related]
43. Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection.
Li H; Wawrose JS; Gooding WE; Garraway LA; Lui VW; Peyser ND; Grandis JR
Mol Cancer Res; 2014 Apr; 12(4):571-82. PubMed ID: 24425785
[TBL] [Abstract][Full Text] [Related]
44. Mutant HRas Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma.
Wang J; Al-Majid D; Brenner JC; Smith JD
Target Oncol; 2023 Sep; 18(5):643-655. PubMed ID: 37665491
[TBL] [Abstract][Full Text] [Related]
45. Exploring the regulatory interactions between mutated genes and homeobox genes in the head and neck cancer progression.
Padam KSR; Chakrabarty S; Hunter KD; Radhakrishnan R
Arch Oral Biol; 2024 Mar; 159():105872. PubMed ID: 38147801
[TBL] [Abstract][Full Text] [Related]
46. Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma.
Hanemaaijer SH; van Gijn SE; Oosting SF; Plaat BEC; Moek KL; Schuuring EM; van der Laan BFAM; Roodenburg JLN; van Vugt MATM; van der Vegt B; Fehrmann RSN
Oral Oncol; 2018 May; 80():33-39. PubMed ID: 29706186
[TBL] [Abstract][Full Text] [Related]
47. Differential alterations of the genes in the CDKN2A-CCND1-CDK4-RB1 pathway are associated with the development of head and neck squamous cell carcinoma in Indian patients.
Tripathi Bhar A; Banerjee S; Chunder N; Roy A; Sengupta A; Roy B; Roychowdhury S; Panda CK
J Cancer Res Clin Oncol; 2003 Nov; 129(11):642-50. PubMed ID: 14586645
[TBL] [Abstract][Full Text] [Related]
48. Immune gene expression in head and neck squamous cell carcinoma patients.
Lecerf C; Kamal M; Vacher S; Chemlali W; Schnitzler A; Morel C; Dubot C; Jeannot E; Meseure D; Klijanienko J; Mariani O; Borcoman E; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Choussy O; Hoffmann C; Piaggio E; Bieche I; Le Tourneau C
Eur J Cancer; 2019 Nov; 121():210-223. PubMed ID: 31593831
[TBL] [Abstract][Full Text] [Related]
49. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
50. [FGFR-targeted therapy in head and neck carcinomas].
Dietrich D
HNO; 2021 Mar; 69(3):172-184. PubMed ID: 32519203
[TBL] [Abstract][Full Text] [Related]
51. A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.
Mazumdar T; Byers LA; Ng PK; Mills GB; Peng S; Diao L; Fan YH; Stemke-Hale K; Heymach JV; Myers JN; Glisson BS; Johnson FM
Mol Cancer Ther; 2014 Nov; 13(11):2738-50. PubMed ID: 25193510
[TBL] [Abstract][Full Text] [Related]
52. EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.
Nelhűbel GA; Cserepes M; Szabó B; Türk D; Kárpáti A; Kenessey I; Rásó E; Barbai T; Hegedűs Z; László V; Szokol B; Dobos J; Őrfi L; Tóvári J
Pathol Oncol Res; 2021; 27():620256. PubMed ID: 34257586
[No Abstract] [Full Text] [Related]
53. Human papillomavirus insertions identify the PIM family of serine/threonine kinases as targetable driver genes in head and neck squamous cell carcinoma.
Broutian TR; Jiang B; Li J; Akagi K; Gui S; Zhou Z; Xiao W; Symer DE; Gillison ML
Cancer Lett; 2020 Apr; 476():23-33. PubMed ID: 31958486
[TBL] [Abstract][Full Text] [Related]
54. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
[TBL] [Abstract][Full Text] [Related]
55. Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
Zumsteg ZS; Morse N; Krigsfeld G; Gupta G; Higginson DS; Lee NY; Morris L; Ganly I; Shiao SL; Powell SN; Chung CH; Scaltriti M; Baselga J
Clin Cancer Res; 2016 Apr; 22(8):2009-19. PubMed ID: 26589432
[TBL] [Abstract][Full Text] [Related]
56. Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway.
García-Escudero R; Segrelles C; Dueñas M; Pombo M; Ballestín C; Alonso-Riaño M; Nenclares P; Álvarez-Rodríguez R; Sánchez-Aniceto G; Ruíz-Alonso A; López-Cedrún JL; Paramio JM; Lorz C
Oral Oncol; 2018 Apr; 79():55-63. PubMed ID: 29598951
[TBL] [Abstract][Full Text] [Related]
57. Targeting Harvey rat sarcoma viral oncogene homolog in head and neck cancer: how to move forward?
Ben Yahia H; Petit FM; Saada-Bouzid E
Curr Opin Oncol; 2023 May; 35(3):178-185. PubMed ID: 36966498
[TBL] [Abstract][Full Text] [Related]
58. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.
Jameson MJ; Beckler AD; Taniguchi LE; Allak A; Vanwagner LB; Lee NG; Thomsen WC; Hubbard MA; Thomas CY
Mol Cancer Ther; 2011 Nov; 10(11):2124-34. PubMed ID: 21878657
[TBL] [Abstract][Full Text] [Related]
59. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions.
Yoshino T; Pentheroudakis G; Mishima S; Overman MJ; Yeh KH; Baba E; Naito Y; Calvo F; Saxena A; Chen LT; Takeda M; Cervantes A; Taniguchi H; Yoshida K; Kodera Y; Kitagawa Y; Tabernero J; Burris H; Douillard JY
Ann Oncol; 2020 Jul; 31(7):861-872. PubMed ID: 32272210
[TBL] [Abstract][Full Text] [Related]
60. Effect of actionable somatic mutations on racial/ethnic disparities in head and neck cancer prognosis.
Wu ES; Park JY; Zeitouni JA; Gomez CR; Reis IM; Zhao W; Kwon D; Lee E; Nelson OL; Lin HY; Franzmann EJ; Savell J; McCaffrey TV; Goodwin WJ; Hu JJ
Head Neck; 2016 Aug; 38(8):1234-41. PubMed ID: 27028310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
